All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Animal model of bronchial asthma

Animal model of bronchial asthma

Explore more

Bronchial asthma
Respiratory disease model

On this page

Model Introduction

Model Introduction

Platform Service Advantages

Platform Service Advantages

Experimental results

Experimental results

Publish an article

View more

Bronchial asthma

Introduction to Animal Models of Bronchial Asthma

Animal models of bronchial asthma commonly employ laboratory rodents such as mice, rats, and guinea pigs. These models are typically established through a two-step protocol involving sensitization with allergens like ovalbumin followed by challenge. By administering aerosols or intraperitoneal injections, researchers can induce in these animals hallmark asthmatic pathophysiological and behavioral features, including airway hyperresponsiveness, airway inflammation, increased mucus secretion, and airway remodeling. Such models closely mimic the clinical manifestations of human asthma—acute exacerbations, chronic inflammation, and pathological changes—and are widely utilized for investigating the underlying mechanisms of asthma, screening therapeutic agents, and evaluating drug efficacy.

Service Advantages of the Aniphe BioLablogical Bronchial Asthma Animal Model Platform

The Aniphe BioLab bronchial asthma animal model platform boasts a mature experimental protocol, diverse model types, comprehensive assay capabilities, standardized environmental conditions, and flexible service options, enabling it to efficiently meet a wide range of research needs.

Comprehensive model coverage

Modeling standards are stable.

A classic OVA sensitization–challenge model is employed, yielding a high success rate and excellent experimental reproducibility.

Standardization of the modeling process

A wide variety of model categories

It can be used to establish various asthma models, including acute and chronic forms as well as dust mite–induced models, thereby accommodating diverse research objectives.

Multidimensional Evaluation System

The testing system has been improved.

Provides multi-dimensional metric monitoring to comprehensively validate model performance and drug efficacy.

Adapted for multi-cycle studies

Experimental environment compliance

Relying on SPF-grade animal facilities, we ensure the accuracy of experimental data.

Standardization of Data Delivery

Flexible and comprehensive services

We offer one-stop experimental services and also support customized solutions.

Modeling cycle

4–6 weeks

1  Laboratory animals

Balb/c female mice

1  Positive drug

Dexamethasone (Dex)

1  Application areas

It is primarily used for research on the pathogenesis of asthma, screening of antiasthmatic and anti-inflammatory drugs, and evaluation of drug efficacy and safety; it can also support the R&D and testing of related formulations, delivery technologies, and combination therapies.

Experimental results

Establishment of an Animal Model of Bronchial Asthma

Asthma model: Established by ovalbumin (OVA) sensitization and challenge. On days 1 and 14, mice were sensitized via intraperitoneal injection of OVA emulsified in aluminum hydroxide; from days 22 to 28, OVA in saline was administered by tracheal instillation into the lungs.

References:

Correlation between the construction of a steroid-resistant asthma Balb/c mouse model and the MAPK signaling pathway.

4-Carvomenthenol ameliorates the murine combined allergic rhinitis and asthma syndrome by inhibiting IL-13 and mucus production via p38MAPK/NF-κB signaling pathway axis.

The effect of the Qingfei Tongluo formula on ILC3s in the lung tissue of asthmatic mice.

H&E staining and pathological scoring

Based on hematoxylin–eosin staining and pathological scoring of lung tissue: the normal control group exhibited well‑organized lung architecture with no signs of inflammation; in the model group (Vehicle), airway inflammation was severe, with disorganized tissue architecture and a markedly elevated pathological score, indicating successful establishment of the asthma model; in the dexamethasone positive‑control group (Dex), inflammation was significantly attenuated and the pathological score was substantially reduced, demonstrating that the drug exerted a clear ameliorative effect on asthma‑related pathological damage.

 

 

 

 

HE staining results

BALF inflammatory cell count

The results of cell differential counts in bronchoalveolar lavage fluid (BALF) showed that, compared with the Normal group, the OVA‑induced Vehicle model group exhibited significantly elevated levels of total cells, lymphocytes, basophils, eosinophils, and macrophages (P<0.001), indicating a pronounced airway inflammatory response in the asthma model. In contrast, compared with the Vehicle group, the Dex‑treated positive‑control group demonstrated a significant reduction in the numbers of all inflammatory cell types (P<0.001), suggesting that dexamethasone can effectively suppress the recruitment of inflammatory cells into the airways of the asthma model and attenuate allergic airway inflammation.

 

 

Serum IgE assay

The results of IL‑5 measurement in bronchoalveolar lavage fluid (BALF) and serum IgE levels showed that, compared with the Normal group, both the BALF IL‑5 level and the serum IgE concentration were significantly elevated in the OVA‑induced Vehicle model group (P<0.001), indicating successful induction of Th2‑type inflammation and allergic responses in the asthma model. Furthermore, compared with the Vehicle group, the Dex‑treated positive‑control group exhibited significantly reduced levels of IL‑5 and IgE (P<0.001), suggesting that dexamethasone effectively suppresses Th2‑type inflammation and IgE‑mediated allergic reactions in the asthma model.